Clinically, Galectin-3 expression showed a strong correlation with β-catenin-IGFBP3/vimentin signalling in HCC samples, a high level of which was associated with vascular metastasis-driven sorafenib resistance and a poor prognosis in patients with HCC. The gene discussed is IGFBP3; the disease is hepatocellular carcinoma.